Cancer therapy developer ADC has attracted $76m to extend its series E round, after AstraZeneca supported a $200m initial tranche in 2017.
Switzerland-based oncology drug developer ADC Therapeutics yesterday received $76m in additional series E financing to bring the round, already backed by pharmaceutical firm AstraZeneca, to a $276m close.
The additional capital was supplied by unnamed existing and new investors. The first tranche was led by private equity firm Auven Therapeutics in late 2017 and, apart from AstraZeneca, also featured hedge fund Redmile, Wild Family Office and undisclosed additional backers.
ADC is working on antibody drug conjugates that target haematological…
